Enliven Therapeutics Inc. (Nasdaq: ELVN) reported this week that as of the end of 2025, the clinical-stage precision oncology company has $462.6 million in cash and equivalents, enough runway to fund ...

Our two top picks for pain-free tax prep in 2026 face off on ease of use, coverage, support, mobile apps, and more. I write about money. I’ve been reviewing tax software and services as a freelancer ...